BACKGROUND: Glucocorticoid prophylaxis is required in some instances after radioiodine (RAI) treatment for Graves' hyperthyroidism to prevent progression of Graves' orbitopathy (GO). However, no randomized clinical trial has been performed to ascertain the optimum glucocorticoid therapy. AIM AND METHODS: Aim of this study was to perform a questionnaire-based survey of glucocorticoid prophylaxis among European thyroidologist members of the European Thyroid Association. RESULTS: Eighty-two responses from 25 European Countries were received. Two respondents did not prescribe steroids in any clinical scenario, while 8 gave the drug to all patients receiving RAI therapy. The majority of respondents only gave glucocorticoids to patients showing some degree of ocular involvement or if risk factors for the progression of GO after RAI were present (e.g., cigarette smoking); 24% of responses indicated that clinicians would not give glucocorticoids if patients were thought to have no GO or inactive GO. Ninety-one percent of clinicians used prednisone (53%) or prednisolone (38%). The mean starting dose [given for 16 days (range 2-60 days)] was 37.6 mg prednisone or prednisone-equivalent (range 15-80 mg). Overall, the results of this survey showed a wide diversity in the regimens used, in terms of timing of initiation of treatment, duration of treatment, cumulative doses of administered glucocorticoids and monitoring of side-effects of glucocorticoid treatment. CONCLUSIONS: The results of this study underscore the need for randomized clinical trials to ascertain the optimum regimen of prophylactic glucocorticoid therapy.
BACKGROUND: Glucocorticoid prophylaxis is required in some instances after radioiodine (RAI) treatment for Graves' hyperthyroidism to prevent progression of Graves' orbitopathy (GO). However, no randomized clinical trial has been performed to ascertain the optimum glucocorticoid therapy. AIM AND METHODS: Aim of this study was to perform a questionnaire-based survey of glucocorticoid prophylaxis among European thyroidologist members of the European Thyroid Association. RESULTS: Eighty-two responses from 25 European Countries were received. Two respondents did not prescribe steroids in any clinical scenario, while 8 gave the drug to all patients receiving RAI therapy. The majority of respondents only gave glucocorticoids to patients showing some degree of ocular involvement or if risk factors for the progression of GO after RAI were present (e.g., cigarette smoking); 24% of responses indicated that clinicians would not give glucocorticoids if patients were thought to have no GO or inactive GO. Ninety-one percent of clinicians used prednisone (53%) or prednisolone (38%). The mean starting dose [given for 16 days (range 2-60 days)] was 37.6 mg prednisone or prednisone-equivalent (range 15-80 mg). Overall, the results of this survey showed a wide diversity in the regimens used, in terms of timing of initiation of treatment, duration of treatment, cumulative doses of administered glucocorticoids and monitoring of side-effects of glucocorticoid treatment. CONCLUSIONS: The results of this study underscore the need for randomized clinical trials to ascertain the optimum regimen of prophylactic glucocorticoid therapy.
Authors: Luigi Bartalena; Lelio Baldeschi; Alison Dickinson; Anja Eckstein; Pat Kendall-Taylor; Claudio Marcocci; Maarten Mourits; Petros Perros; Kostas Boboridis; Antonella Boschi; Nicola Currò; Chantal Daumerie; George J Kahaly; Gerasimos E Krassas; Carol M Lane; John H Lazarus; Michele Marinò; Marco Nardi; Christopher Neoh; Jacques Orgiazzi; Simon Pearce; Aldo Pinchera; Susanne Pitz; Mario Salvi; Paolo Sivelli; Matthias Stahl; Georg von Arx; Wilmar M Wiersinga Journal: Eur J Endocrinol Date: 2008-03 Impact factor: 6.664
Authors: Shamasunder H Acharya; Alison Avenell; Sam Philip; Jennifer Burr; John S Bevan; Prakash Abraham Journal: Clin Endocrinol (Oxf) Date: 2008-04-21 Impact factor: 3.478
Authors: L Bartalena; C Marcocci; F Bogazzi; L Manetti; M L Tanda; E Dell'Unto; G Bruno-Bossio; M Nardi; M P Bartolomei; A Lepri; G Rossi; E Martino; A Pinchera Journal: N Engl J Med Date: 1998-01-08 Impact factor: 91.245